Immunotherapy for Multiple Myeloma — Which Approaches, and Who They Are For

Most patients are not candidates for the newest immune treatments. Eligibility depends on which approach is meant. Antibody-based treatment is used widely, including from the first line and in patients not fit for a transplant. Bispecific antibodies and CAR-T cell therapy come after several previous lines, and Indian access is limited.

Age alone decides less than families expect. What the team assesses is fitness: how you manage day to day, kidney function, blood counts, heart and lung health, and other illnesses. An older or frailer patient is far more often offered a dose-adjusted combination than offered nothing at all. Ask for a frailty assessment by name.

Medical history matters differently here than with checkpoint blockade. These approaches do not work by releasing brakes on the whole immune system, so a history of autoimmune disease is less often the deciding factor. Uncontrolled infection, very low blood counts, significant kidney impairment and existing nerve damage weigh more heavily.

One situation needs a specialist call rather than a general rule. If a donor (allogeneic) stem-cell transplant has already been done, any further immune treatment is decided with the transplant centre, because of the risk of provoking graft-versus-host disease.

Nothing on this page decides eligibility. That rests on the bone-marrow report, the blood and urine protein tests, kidney function, imaging of the bones and the treatments already given, read together by a medical or haemato-oncologist.

Four distinct approaches, used at different points. Immunomodulatory tablets have been part of standard treatment for two decades. Antibody therapy against a marker on plasma cells is now part of standard combinations. Bispecific antibodies and CAR-T cell therapy sit later, after several lines. Each has a different setting, a different risk profile and a different place of delivery.

This table describes the general sequence recognised by guideline bodies such as NCCN and ESMO. What is actually approved and available in India, and at which point, is changing quickly. Confirm current CDSCO approval status and centre availability with the treating team at the time the decision is made, not from any page written earlier.

There is no single figure, and any figure is indicative only, as of August 2026. Cost follows which approach is used, how many drugs are combined, how often infusions are given, and how long treatment continues. In myeloma that is usually years, so the honest unit is a monthly running cost, not a one-time bill.

Four things move the number more than anything else. Whether an antibody infusion is part of the combination. How frequently that infusion is given, which is typically closer together at the start and further apart later. Whether treatment continues as maintenance after the initial phase. And supportive care, which in myeloma is not optional: bone-strengthening treatment, infection prevention, and antibody replacement where levels are very low.

Prices do move downwards as well as up. Biosimilar versions of some antibodies have reduced costs in India, and more are expected. That is one reason to ask for a fresh written estimate at each line of treatment rather than relying on a figure quoted a year ago.

The high-cost end sits outside CION. Bispecific antibodies and CAR-T cell therapy are among the most expensive cancer treatments anywhere in the world, and where they are used they are billed by the designated centre providing them, not by us. Ask that centre directly, in writing, and ask what is included and what is not.

Cover is worth settling before treatment starts, not after the first cycle. ArogyaSri, CGHS, ECHS, ESI and cashless insurance each cover different parts of a myeloma pathway, and day-care billing and inpatient billing are not treated the same way. Our team will help check what applies and get it confirmed in writing. Costs across the wider blood-cancer pathway are set out in more detail in Immunotherapy for Leukaemia, where the same cost structure applies.

Because in myeloma the immune system is already weakened, not merely held back. Myeloma is a cancer of plasma cells, the cells that normally make antibodies. As it grows, normal antibody production falls and the marrow environment suppresses the T cells around it. Releasing a brake is not much use when the engine is already tired.

That is the practical reason checkpoint blockade did not translate here. It works best where T cells have already found the cancer and been switched off at the last step. In myeloma, the more productive strategies have been ones that supply direction rather than permission.

Antibody therapy supplies direction in the simplest way. Myeloma cells display particular surface proteins densely and consistently, which makes them an unusually good address label. An antibody attaches there and marks the cell for clearance.

Bispecific antibodies and CAR-T go further. One arm holds a T cell, the other holds the myeloma cell, so the two are brought together whether or not the T cell would have found it alone. CAR-T does the same thing by re-engineering the T cells themselves. Both are powerful, and both carry early risks that are the reason they start as an inpatient.

The same biology explains the risk that follows every myeloma patient into survivorship. Normal antibody levels are low from the disease and can fall further with treatment, which is why infection, not the cancer alone, is often what puts someone in hospital. Low immunoglobulins and infection risk after blood cancer immunotherapy covers what that means day to day and when antibody replacement is considered.

No. CION does not provide CAR-T or any other cell therapy, and does not perform stem-cell transplants. Both are carried out at designated centres. What CION provides is medical oncology assessment, tumour-board review, day-care immunotherapy where it is indicated, and coordination of the referral so the handover is not left to the family to organise.

For fit patients, an autologous stem-cell transplant using their own stem cells remains a standard step after initial treatment, carried out at a designated transplant centre. It is planned early, because some drug choices affect how well stem cells can later be collected. Donor transplant is used far less often in myeloma.

CAR-T is the part families ask about most, and the honest position is that it is a fast-moving field with limited Indian availability. Approved products elsewhere are directed at a marker myeloma cells carry, and are used after several previous lines rather than early. CAR-T is better established in some leukaemias and B-cell lymphomas, as Immunotherapy for Leukaemia sets out. Which products are approved by CDSCO for myeloma, and at which Indian centres, should be checked at the time, not assumed.

Bispecific antibodies follow a similar pattern. They are started as an inpatient with step-up dosing, because cytokine release syndrome and neurological effects are most likely in the early doses. Once that phase is complete, later dosing may be able to move closer to home if the treating centre agrees to shared care.

If a clinical trial is the right conversation, it is an informational one. A trial is not a promise of a place, and an investigational treatment is by definition one whose benefit is still being established. Ask the treating team what is open, where, and what taking part would involve.

• Infection is the risk that gets underestimated — ask what antibody levels are, who monitors them, and what to do about fever. A fever needs same-day contact, not a wait-and-see.
• For an older or frailer patient, ask for a frailty assessment — the useful question is which dose-adjusted combination fits, not whether to treat at all. Ask what would change if it is not tolerated.
• For a younger patient, plan for decades — raise fertility before stem cells are collected, and ask who monitors long-term effects. Data on the newest immune treatments is still maturing.
• Ask about bones and kidneys, not just the cancer — myeloma damages both. Bone-strengthening treatment, a dental check before it, and hydration advice belong in the plan from day one.
• Get cost and cover in writing before starting — all figures are indicative, as of August 2026. Ask which parts recur monthly, and which scheme or policy covers what.

• CAR-T is further established in some leukaemias than in myeloma, and the cost structure across blood cancers is the same — Immunotherapy for Leukaemia sets out both.
• Low antibody levels are the reason infection, not the cancer, often lands a myeloma patient in hospital — Low Immunoglobulins and Infection Risk After Blood Cancer Immunotherapy explains monitoring and replacement.
• If a donor transplant is part of the history or the plan, one complication shapes every later decision — Graft-Versus-Host Disease After Transplant covers what to watch for.
• For how immunotherapy is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Still unsure how any of this applies to a specific myeloma diagnosis? Book a free consultation and a medical oncologist will go through the reports with you.